• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpene glycosides
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Terpene glycosides Triterpene glycosides
• Triterpenoids

Diammonium glycyrrhizinate (CAS No. 79165-06-3): A Comprehensive Overview

Diammonium glycyrrhizinate, with the chemical formula corresponding to its CAS number 79165-06-3, is a compound derived from the root of the licorice plant (Glycyrrhiza glabra). This compound has garnered significant attention in the field of pharmaceuticals and nutraceuticals due to its multifaceted therapeutic properties. The use of Diammonium glycyrrhizinate has been extensively studied for its potential applications in various medical conditions, ranging from anti-inflammatory and antiviral effects to its role in liver protection and immune modulation.

The primary active component in licorice, glycyrrhizin, is often converted into its ammonium salt form, Diammonium glycyrrhizinate, to enhance solubility and bioavailability. This transformation not only improves the compound's pharmacokinetic profile but also expands its therapeutic potential. Recent studies have highlighted the compound's efficacy in managing liver-related disorders, including chronic hepatitis and liver cirrhosis. The anti-inflammatory and antioxidant properties of Diammonium glycyrrhizinate have been demonstrated to protect hepatocytes from oxidative stress and inflammation-induced damage.

One of the most compelling aspects of Diammonium glycyrrhizinate is its ability to modulate immune responses. Research has shown that it can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, thereby reducing systemic inflammation. This immunomodulatory effect makes it a promising candidate for treating autoimmune diseases and chronic inflammatory conditions. Additionally, studies have explored its potential role in managing allergic reactions by suppressing histamine release from mast cells.

The anti-viral properties of Diammonium glycyrrhizinate have also been a subject of intense research. Studies have indicated that it can inhibit the replication of various viruses, including herpes simplex virus (HSV) and hepatitis C virus (HCV). The mechanism behind this anti-viral activity involves the inhibition of viral enzymes and the disruption of viral protein synthesis. These findings suggest that Diammonium glycyrrhizinate could be a valuable adjuvant therapy in combination with conventional antiviral drugs.

In terms of clinical applications, Diammonium glycyrrhizinate has been used in traditional medicine for centuries due to its perceived health benefits. Modern pharmacological research has validated many of these traditional uses, paving the way for its integration into contemporary healthcare systems. The compound's safety profile has been evaluated in multiple clinical trials, demonstrating low toxicity even at high doses. This makes it a suitable candidate for long-term therapeutic use.

The pharmacokinetics of Diammonium glycyrrhizinate have been thoroughly investigated to optimize its therapeutic efficacy. Studies have shown that it exhibits good oral bioavailability and a prolonged half-life, allowing for once-daily dosing regimens. This attribute is particularly beneficial for patient compliance and convenience. Furthermore, the compound's ability to cross the blood-brain barrier has opened up possibilities for treating neurological disorders associated with inflammation and oxidative stress.

Recent advancements in drug delivery systems have enhanced the formulation of Diammonium glycyrrhizinate into more effective therapeutic agents. Nanoparticle-based formulations have been developed to improve drug delivery efficiency and target specificity. These innovations are expected to expand the therapeutic applications of Diammonium glycyrrhizinate into areas such as cancer therapy and neuroprotection.

The economic impact of Diammonium glycyrrhizinate as a pharmaceutical ingredient cannot be overstated. The growing demand for natural health products has driven significant investment in licorice-based compounds like Diammonium glycyrrhizinate. This trend is expected to continue as consumers seek safer and more effective alternatives to synthetic drugs.

Future research directions include exploring the potential synergistic effects of Diammonium glycyrrhizinate with other bioactive compounds. Combining it with phytochemicals such as curcumin or resveratrol could lead to novel therapeutic strategies with enhanced efficacy against various diseases.

• 911217-00-0(a-D-Glucopyranosiduronic acid, (3b,20b)-20-carboxy-11-oxo-30-norolean-12-en-3-yl2-O-b-D-glucopyranuronosyl-, monoammoniumsalt, trihydrate (9CI))
• 103000-77-7(b-D-Glucopyranosiduronic acid, (3b,20b)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-b-D-glucopyranuronosyl-)
• 53956-04-0(Ammonium glycyrrhizinate)
• 121687-83-0(b-D-Glucopyranosiduronic acid, (3b,20b)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-a-L-arabinopyranosyl- (9CI))
• 137476-70-1(b-D-Glucopyranosiduronic acid, (3b,20b)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 4-O-b-D-glucopyranuronosyl- (9CI))
• 1407-03-0(GLYCYRRHIZIC ACID AMMONIUM SALT)
• 1405-86-3(Glycyrrhizic acid)
• 34096-83-8(Glycyrrhetic acid 3-O-β-D-glucuronide)
• 105038-43-5(b-D-Glucopyranosiduronic acid, (3b,20b)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 3-O-b-D-glucopyranuronosyl-)
• 207300-84-3(a-D-Glucopyranosiduronic acid, (3b,20b)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-b-D-glucopyranuronosyl-,monoammonium salt, hydrate (9CI))